Cellular factors may enable squamous carcinoma cells to overcome TGFβ- mediated repression of CDK2 activity

E. E. Lesaca, J. F. Ensley, William Andrew Yeudall

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cell lines developed from head and neck squamous cell carcinomas exhibit variable responses to the negative regulatory effects of transforming growth factor β (TGFβ) on cell growth. To analyse the effects of TGFβ on regulators of cell cycle progression, we characterised cell lines derived from head and neck squamous cell carcinoma (HNSCC) for their biological sensitivities to TGFβ, growth inhibition, then examined the effects of TGFβ treatment on the expression and activity of cyclin dependent kinases (CDKs) and inhibitors of these kinases. Western blot analysis of cell lysates from untreated or TGFβ-treated cultures showed no alterations in expression of CDK2, CDK4, CDK6 or cyclin E in cell lines which were either sensitive (HaCaT, HN6) or refractory (HN12, HN30) to the growth-inhibitory effects of TGFβ. However, treatment of cells with TGFβ resulted in a several fold increase in cellular levels of p21 (WAF1/Cip1), irrespective of biological response. Immune complex in vitro kinase assays demonstrated that the activity of CDK2 was inhibited by exposure to ligand in each case, confirming that a TGFβ signalling pathway which regulates kinase activity was intact in these cell lines. The data suggest that cellular factors expressed in HN12 and HN30 enable these cells to override TGFβ-mediated inhibition of CDK2 activity and allow cell cycle progression. This may represent an important mechanism which allows cells to evade growth arrest during malignant progression.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalOral Oncology
Volume34
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Transforming Growth Factors
Squamous Cell Carcinoma
Cell Line
Phosphotransferases
Growth
Cell Cycle
Cyclin E
Cyclin-Dependent Kinases
Antigen-Antibody Complex
Western Blotting
Ligands

Keywords

  • Cell cycle
  • Cip1
  • Cyclin dependent kinase
  • Oral cancer
  • Squamous cell carcinoma
  • Transforming growth factor
  • WAF1
  • p21

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Cellular factors may enable squamous carcinoma cells to overcome TGFβ- mediated repression of CDK2 activity. / Lesaca, E. E.; Ensley, J. F.; Yeudall, William Andrew.

In: Oral Oncology, Vol. 34, No. 1, 01.01.1998, p. 52-57.

Research output: Contribution to journalArticle

@article{10ba8cab50ef4fa8957af5ad15874470,
title = "Cellular factors may enable squamous carcinoma cells to overcome TGFβ- mediated repression of CDK2 activity",
abstract = "Cell lines developed from head and neck squamous cell carcinomas exhibit variable responses to the negative regulatory effects of transforming growth factor β (TGFβ) on cell growth. To analyse the effects of TGFβ on regulators of cell cycle progression, we characterised cell lines derived from head and neck squamous cell carcinoma (HNSCC) for their biological sensitivities to TGFβ, growth inhibition, then examined the effects of TGFβ treatment on the expression and activity of cyclin dependent kinases (CDKs) and inhibitors of these kinases. Western blot analysis of cell lysates from untreated or TGFβ-treated cultures showed no alterations in expression of CDK2, CDK4, CDK6 or cyclin E in cell lines which were either sensitive (HaCaT, HN6) or refractory (HN12, HN30) to the growth-inhibitory effects of TGFβ. However, treatment of cells with TGFβ resulted in a several fold increase in cellular levels of p21 (WAF1/Cip1), irrespective of biological response. Immune complex in vitro kinase assays demonstrated that the activity of CDK2 was inhibited by exposure to ligand in each case, confirming that a TGFβ signalling pathway which regulates kinase activity was intact in these cell lines. The data suggest that cellular factors expressed in HN12 and HN30 enable these cells to override TGFβ-mediated inhibition of CDK2 activity and allow cell cycle progression. This may represent an important mechanism which allows cells to evade growth arrest during malignant progression.",
keywords = "Cell cycle, Cip1, Cyclin dependent kinase, Oral cancer, Squamous cell carcinoma, Transforming growth factor, WAF1, p21",
author = "Lesaca, {E. E.} and Ensley, {J. F.} and Yeudall, {William Andrew}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S1368-8375(97)00023-7",
language = "English (US)",
volume = "34",
pages = "52--57",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Cellular factors may enable squamous carcinoma cells to overcome TGFβ- mediated repression of CDK2 activity

AU - Lesaca, E. E.

AU - Ensley, J. F.

AU - Yeudall, William Andrew

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Cell lines developed from head and neck squamous cell carcinomas exhibit variable responses to the negative regulatory effects of transforming growth factor β (TGFβ) on cell growth. To analyse the effects of TGFβ on regulators of cell cycle progression, we characterised cell lines derived from head and neck squamous cell carcinoma (HNSCC) for their biological sensitivities to TGFβ, growth inhibition, then examined the effects of TGFβ treatment on the expression and activity of cyclin dependent kinases (CDKs) and inhibitors of these kinases. Western blot analysis of cell lysates from untreated or TGFβ-treated cultures showed no alterations in expression of CDK2, CDK4, CDK6 or cyclin E in cell lines which were either sensitive (HaCaT, HN6) or refractory (HN12, HN30) to the growth-inhibitory effects of TGFβ. However, treatment of cells with TGFβ resulted in a several fold increase in cellular levels of p21 (WAF1/Cip1), irrespective of biological response. Immune complex in vitro kinase assays demonstrated that the activity of CDK2 was inhibited by exposure to ligand in each case, confirming that a TGFβ signalling pathway which regulates kinase activity was intact in these cell lines. The data suggest that cellular factors expressed in HN12 and HN30 enable these cells to override TGFβ-mediated inhibition of CDK2 activity and allow cell cycle progression. This may represent an important mechanism which allows cells to evade growth arrest during malignant progression.

AB - Cell lines developed from head and neck squamous cell carcinomas exhibit variable responses to the negative regulatory effects of transforming growth factor β (TGFβ) on cell growth. To analyse the effects of TGFβ on regulators of cell cycle progression, we characterised cell lines derived from head and neck squamous cell carcinoma (HNSCC) for their biological sensitivities to TGFβ, growth inhibition, then examined the effects of TGFβ treatment on the expression and activity of cyclin dependent kinases (CDKs) and inhibitors of these kinases. Western blot analysis of cell lysates from untreated or TGFβ-treated cultures showed no alterations in expression of CDK2, CDK4, CDK6 or cyclin E in cell lines which were either sensitive (HaCaT, HN6) or refractory (HN12, HN30) to the growth-inhibitory effects of TGFβ. However, treatment of cells with TGFβ resulted in a several fold increase in cellular levels of p21 (WAF1/Cip1), irrespective of biological response. Immune complex in vitro kinase assays demonstrated that the activity of CDK2 was inhibited by exposure to ligand in each case, confirming that a TGFβ signalling pathway which regulates kinase activity was intact in these cell lines. The data suggest that cellular factors expressed in HN12 and HN30 enable these cells to override TGFβ-mediated inhibition of CDK2 activity and allow cell cycle progression. This may represent an important mechanism which allows cells to evade growth arrest during malignant progression.

KW - Cell cycle

KW - Cip1

KW - Cyclin dependent kinase

KW - Oral cancer

KW - Squamous cell carcinoma

KW - Transforming growth factor

KW - WAF1

KW - p21

UR - http://www.scopus.com/inward/record.url?scp=0031944138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031944138&partnerID=8YFLogxK

U2 - 10.1016/S1368-8375(97)00023-7

DO - 10.1016/S1368-8375(97)00023-7

M3 - Article

VL - 34

SP - 52

EP - 57

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 1

ER -